These tumours may also be adapting to therapy pressure, undergoing clonal selection, or the gain in HER2 expression may be coinciding with mutations in pathways such as PI3K/AKT, all of which could contribute to a more aggressive clinical course [[50], [51], [52]]. Here, ERBB2 is linked to neoplasm.